# Gilead Sciences, Inc. (GILD)

> Gilead sells medicines for human immunodeficiency virus, liver disease, cancer, and coronavirus disease 2019.

- Exchange: Nasdaq · Sector: Healthcare · Industry: Drug Manufacturers General
- Headquarters: Foster City, California
- Founded: 1987
- Employees: Approximately 17,000 (December 31, 2025)
- SEC CIK: 0000882095 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095))
- Full page: https://inspectstocks.com/stocks/gild
- Data as of: price 2026-09-28; newest filing used 2026-08-06; latest fiscal period ended 2026-06-30

## Grade

**A** on the growth-and-cash rubric, 5 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $30.5B | $27.4B |
| Revenue growing recently | passed | $30.5B | $29.4B |
| Free cash flow positive | passed | $12.9B |  |
| Free cash flow growing overall | passed | $12.9B | $8.9B |
| Free cash flow growing recently | passed | $12.9B | $9.5B |

Business quality (the + / − mark): 2 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -10.6% |  |
| Healthy profit margin | failed | -10.6% |  |
| Strong operating margin | failed | -8.2% |  |
| Good return on equity | failed | -14.3% |  |
| Debt under control | passed | 1.13 |  |
| Turns sales into cash | passed | 42.5% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $30.5B |
| Net income, trailing twelve months | -$3.2B |
| Free cash flow, trailing twelve months | $12.9B |
| Net margin | -10.6% |
| Operating margin | -8.2% |
| Return on equity | -14.3% |
| Debt to equity | 1.13 |
| Diluted EPS, trailing twelve months | -$2.67 |
| Share price | $152.21 |
| Market value | $188.7B |
| Price / sales | 6.2x |

## What the business does

Gilead discovers, develops, and sells prescription medicines. Its medicines prevent or treat human immunodeficiency virus (HIV), viral hepatitis, cancer, coronavirus disease 2019 (COVID-19), and other serious illnesses. It sells medicines directly through its commercial teams and through wholesalers, distributors, and business partners.

### How it makes money

- **HIV medicines** (72.6% (six months ended June 30, 2026)) — Revenue mainly comes from sales of medicines for HIV treatment and pre-exposure prophylaxis, including Biktarvy, Descovy, and Yeztugo.
- **Liver disease medicines** (11.1% (six months ended June 30, 2026)) — Revenue comes from medicines for liver diseases, including Livdelzi, Vemlidy, Hepcludex, and medicines for hepatitis C.
- **Cancer medicines** (11.4% (six months ended June 30, 2026)) — Revenue comes from sales of cell therapies such as Yescarta and Tecartus, and cancer medicines such as Trodelvy.
- **Veklury** (1.1% (six months ended June 30, 2026)) — Revenue comes from sales of remdesivir, a medicine used to treat COVID-19 in certain patients.
- **Royalties, contracts, and other revenue** (1.3% (six months ended June 30, 2026)) — Revenue includes royalties from intellectual property licensed to other companies and payments from collaborations and intellectual property transactions.

### Products

- **Biktarvy** — A daily tablet used to treat HIV infection in certain patients.
- **Yeztugo** — A tablet and long-acting injection used before exposure to help prevent HIV infection in at-risk adults and adolescents.
- **Descovy** — A tablet used with other medicines to treat HIV, and also used before exposure to help prevent HIV infection in certain at-risk people.
- **Trodelvy** — An intravenous medicine for certain adults with advanced breast cancer. The latest quarterly report describes its use as a first-line treatment for metastatic triple-negative breast cancer, as well as treatment for some patients with hormone-receptor-positive breast cancer.
- **Yescarta** — A treatment made from a patient's immune cells that are changed to recognize and attack certain blood cancers.
- **Livdelzi** — An oral medicine for primary biliary cholangitis, a chronic disease that damages small bile ducts in the liver.

### Customers

- In the United States, large drug wholesalers buy most products for distribution to pharmacies and healthcare providers; Gilead names Cardinal Health, Cencora, and McKesson as major wholesalers.
- Outside the United States, products are sold through Gilead's commercial teams, third-party distributors, and corporate partners.
- Hospitals, clinics, and other healthcare providers prescribe or administer Gilead medicines to patients.
- Government health programs and private insurers pay for or reimburse many prescriptions and related treatments.

### Competitors

- ViiV Healthcare (a GSK division) (GSK) — Medicines for HIV treatment and prevention.
- Merck & Co., Inc. (MRK) — Medicines for HIV treatment and cancer; Merck is also a Gilead collaborator on some medicines under development.
- Bristol Myers Squibb (BMY) — Cell therapies and other medicines for blood cancers.
- Novartis AG (NVS) — Cell therapies and other medicines for blood cancers.
- AstraZeneca PLC (AZN) — Medicines for breast cancer and other cancers.

### What it depends on

- Gilead relies on wholesalers to distribute most of its products in the United States and on distributors or corporate partners in some other markets.
- It relies on outside manufacturers and testing laboratories for much of the production and testing of its medicines, though it uses multiple suppliers for many products.
- Its business depends on regulatory approval and continuing compliance with rules governing drug testing, manufacture, safety, promotion, and sale.
- Sales depend on health insurers and government payers covering medicines and on the prices and discounts they accept.

### What could go wrong

- HIV medicines accounted for 72.6% of revenue (six months ended June 30, 2026, high), so changes in demand, competition, coverage, or pricing for those medicines could materially affect sales.
- Clinical trials can fail or be delayed, and regulators can limit or reject a medicine's use. In June 2026, Gilead stopped a Trodelvy study in non-small cell lung cancer and recorded a $1.75 billion impairment charge for the related research asset (three months ended June 30, 2026, high).
- Generic medicines, competing treatments, patent challenges, and required discounts or rebates can reduce sales or the amount Gilead receives for its medicines.

## More on this company

- [Overview](https://inspectstocks.com/stocks/gild)
- [Financial statements](https://inspectstocks.com/stocks/gild/financials)
- [Competitors](https://inspectstocks.com/stocks/gild/peers)
- [Earnings](https://inspectstocks.com/stocks/gild/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.